The Incremental Value of Lipids and Inflammatory B

Authors: Sandeep S Mangalmurti Michael H Davidson

Publish Date: 2011/07/20

Volume: 13, Issue: 5, Pages: 373-

PDF Link

Abstract

With the increasing use of drug therapy and lifestyle modification for primary and secondary prevention of cardiovascular disease there remain questions on how to quantify residual risk particular in patients with diabetes mellitus or obesity Clinicians have turned to other screening modalities to identify individuals who would benefit from even more intensive therapy or to identify those with difficulttoassess risk factors Once a patient has been identified for aggressive risk factor modification lipid biomarkers such as Apo B LDLP and Lp a can potentially have clinical utility and inflammatory markers such as hsCRP may be useful for evaluating residual riskSS Mangalmurti none MH Davidson is a board member of DTMC MD Omthera Professional Evaluation Inc and Sonogene is or has been a consultant for Abbott Aegerion AstraZeneca Atherotech BaiichiSankyo DTMC MD Esperion GlaxoSmithKline iMD Intelligent Medical Decisions Kinemed LipoScience Merck Novo Nordisk Roche sanofiaventis Synarc Takeda and Vindico Medical Education and has received honoraria from Abbott AstraZeneca GlaxoSmithKline and Merck

Keywords: